Have you been told to cut out carbs because of insulin resistance? Big mistake! The key is choosing the right ones. Discover ...

A laboratory on Long Island has found a breakthrough in the fight against pancreatic cancer that can “intercept” its spread.

A preclinical model developed at UT Southwestern Medical Center that recapitulates a rare infant-onset form of diabetes ...

Petrenko V, Sinturel F, Riezman H, Dibner C. Lipid metabolism around the body clocks. Progress in lipid research ...

Pat Gulhati, MD, PhD, discusses findings from a comprehensive analysis of genetic, immunological, and signaling pathway variations in pancreatic cancer.

Pancreatic cancer is on the rise in the United States, but there's another, less common type called pancreatic neuroendocrine ...

The US Food and Drug Administration (FDA) has approved Exelixis’ Cabometyx (cabozantinib) to treat advanced neuroendocrine tumours (NETs).

well-differentiated pancreatic neuroendocrine tumors (pNET) and well-differentiated extra-pancreatic neuroendocrine tumors (epNET). The approval for use in advanced neuroendocrine tumors is supported ...

Exelixis, Inc. EXEL announced that the FDA has approved the label expansion of its lead drug Cabometyx (cabozantinib). The regulatory body approved Cabometyx for the treatment of adult and pediatric ...

Cabometyx is approved for treating well-differentiated pancreatic and extra-pancreatic neuroendocrine ... “Cabometyx is an oral tyrosine kinase inhibitor and inhibits certain receptors on the cell ...